of Cancer Epidemiology and Genetics, said that the JAMA results are "generally consistent with things that we and others have reported.
"They note that incidence rates are rising primarily among young women with estrogen receptor (ER)-positive breast cancers," said Anderson. "There's a negative trend for ER-negative disease. That's exactly the same divergent pattern that we reported in 2011" (see J. Natl. Cancer Inst. 2011; 103:1397-402) . Anderson cited analyses by his group and others showing that the decline in breast cancer diagnoses that occurred in the early 2000s, when mammography rates dropped off slightly and many women went off hormone replacement therapy, appears to have ended and that ER-positive disease is again increasing-not only in the United States but also perhaps in other countries. Moreover, several studies point to a long-term decline in rates of ER-negative disease.
Anderson's 2011 analysis found that, among women aged 30-49 years, the rate of ER-positive breast cancer increased 1.17% per year from 1992 to 2008, whereas the rate of ER-negative cancer decreased 2.42% per year. These trends were projected to continue over the next few years.
According to estimates of the American Cancer Society, some 230,000 U.S. women will receive a diagnosis of invasive breast cancer in 2013. Only about 5% of all cases are diagnosed in women younger than 40 years.
Berry believes that virtually all changes in incidence rates of breast cancer are associated with screening, measurement, or use of hormones. If ER-positive disease is going up and ER-negative disease is going down, Berry said, "the easiest answer is that pathologists have changed something [in how they measure hormone receptors], or mammography is changing the detection of the two types of breast cancer. Maybe digital mammography has an effect. "It's happening so rapidly, it would be a bit strange if this were etiological. If it were happening over 70 years, it would make more sense. But, then again, maybe something else is going on."
Anderson conceded that more sensitive ER tests or lower diagnostic thresholds for ER-positive cancers might contribute to the reduction in ER-negative disease. At the same time, he said, "statistically significantly different birth cohort deviations for ER-positive and ER-negative cancers are consistent with different trends in etiologically distinct entities." Anderson said that these patterns need to be confirmed but added, "If it is truly a cohort effect, certain reproductive, dietary, and hormonal risk factors must do different things to ER-positive and ER-negative breast cancers." For an example, he pointed to childbearing: "As parity goes down, ER-positive disease goes up while ER-negative disease goes down."
Ravdin said that obesity, too, could have a dual effect. He noted that results from the P-1 Breast Cancer Prevention Trial showed that obesity selectively increases the proportion of ER-positive breast cancer in premenopausal but not postmenopausal women. Then he added, "Perhaps speculating about the mechanisms of an effect that arguably may or may not be real is getting ahead of the game." Why the inconsistency? Beyond the possibility of faulty memories of study participants filling out questionnaires, Steven Freedland, M.D., associate professor of surgery at Duke University Medical Center in Durham, N.C., believes he knows why. "To me, the androgen hypothesis is not wrong; it just means we've been looking in the wrong place. We should be examining the tissue, not serum levels, which doesn't accurately reflect what's going on in the prostate."
Freedland cowrote one of the new studies, which examined 312 healthy control subjects, 167 men with prostate cancer, and 229 men without prostate cancer at a Veterans Affairs Hospital. Participants self-described their hair patterns at ages 30 and 40 years. "We tested the association between hair pattern-overall, vertex, or frontal-and prostate cancer status by using logistic regression analysis adjusting for multiple clinical features," Freedland said.
In relation to controls, the researchers found that a younger age of AA onset was statistically significantly MF: This is correct as is. associated with increased prostate cancer risk. The study noted similar patterns for frontal, but not vertex, balding. "Overall balding was associated with greater than twofold increase in high-grade disease," Freedland said. "Although our study was not specifically African American men, they comprised nearly 50% of the cohort." The study appeared in the March 26, 2013, issue of Cancer Causes and Control.
A study dealing specifically with African American men found that advanced prostate cancer increased with younger age and type of baldness. Conducted by researchers at the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania in Philadelphia, the study consisted of 318 men with prostate cancer and 219 control subjects enrolled in the Study of Clinical Outcomes, Risk, and Ethnicity (SCORE) between 1998 and 2010. Lead researcher Charnita Zeigler-Johnson, Ph.D., research assistant professor at the University of Pennsylvania, said that this study is the first to examine these associations in an allAfrican American sample and one of a few studies to examine results by age groups.
In the study, which appeared in the March 2013 Cancer Epidemiology, Biomarkers, and Prevention, the researchers determined age-stratified associations of baldness with prostate cancer occurrence and severity defined by high stage (T3/T4) or high-grade Gleason scores (7+.) Bald men, regardless of hair loss type, had a 69% greater risk of prostate cancer, and young men with frontal hair loss were six times more likely than those without such baldness to get advanced prostate cancer by age 60 years. Frontal hair loss was also associated with higher cancer risk than vertex baldness.
The Androgen Links
Zeigler-Johnson said that the link between male pattern baldness and prostate cancer is believed to be tied to dihydrotestosterone, which is linked to benign and cancerous growth of the prostate gland and contributes to hair follicle shrinkage, which can cause hair thinning. Daniel S. Blumenthal, M.D., former director of the Cancer Group at Morehouse School of Medicine in Atlanta and president-elect of the American College of Preventive Medicine, said that although the studies are interesting, the conclusions are unlikely to affect clinical practice much. "This is especially true since the studies are inconsistent with each other as far as types of baldness. Also, I think that hair loss is too variable a phenomenon to be useful clinically in an individual patient."
Zeigler-Johnson said that the differences between types of baldness are duly noted and need to be reconciled. "Still, all these recent findings are exciting and novel, and no doubt need to be confirmed by additional research." 
